[
  {
    "ts": null,
    "headline": "ASH 2024: Regeneron’s Ordspono faces challenges, but positive results signal hope",
    "summary": "While 88.1% of patients completed one cycle, patient adherence beyond the fourth cycle was relatively low.",
    "url": "https://finnhub.io/api/news?id=05553ad9bdc8089e195930b54d6f93dc6c2af1c01ea6243403c1de7bd75ba40f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1733861180,
      "headline": "ASH 2024: Regeneron’s Ordspono faces challenges, but positive results signal hope",
      "id": 131912255,
      "image": "https://live-b2b-gdm-figaro1.pantheonsite.io/wp-content/uploads/sites/24/2024/12/shutterstock_1665700435.jpg",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "While 88.1% of patients completed one cycle, patient adherence beyond the fourth cycle was relatively low.",
      "url": "https://finnhub.io/api/news?id=05553ad9bdc8089e195930b54d6f93dc6c2af1c01ea6243403c1de7bd75ba40f"
    }
  },
  {
    "ts": null,
    "headline": "Regeneron Pharmaceuticals (REGN): Sales Struggles and Future Prospects",
    "summary": "We recently published a list of Jim Cramer’s Lightning Rounds: 12 Stocks Under the Spotlight. In this article, we are going to take a look at where Regeneron (NASDAQ:REGN) stands against other stocks under Jim Cramer’s lightning rounds’ spotlight. Jim Cramer, host of Mad Money, recently discussed the outlook for the stock market following a […]",
    "url": "https://finnhub.io/api/news?id=de80fb2686f7e23bf6d91f638ff205f76109bc6dafae07fb26ee792e0db5a92f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1733850260,
      "headline": "Regeneron Pharmaceuticals (REGN): Sales Struggles and Future Prospects",
      "id": 131912256,
      "image": "https://media.zenfs.com/en/insidermonkey.com/dc5a2bcb6b4c16a43cb5b4ba98feb139",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "We recently published a list of Jim Cramer’s Lightning Rounds: 12 Stocks Under the Spotlight. In this article, we are going to take a look at where Regeneron (NASDAQ:REGN) stands against other stocks under Jim Cramer’s lightning rounds’ spotlight. Jim Cramer, host of Mad Money, recently discussed the outlook for the stock market following a […]",
      "url": "https://finnhub.io/api/news?id=de80fb2686f7e23bf6d91f638ff205f76109bc6dafae07fb26ee792e0db5a92f"
    }
  },
  {
    "ts": null,
    "headline": "Regeneron Pharmaceuticals Inc. stock underperforms Tuesday when compared to competitors",
    "summary": "Regeneron Pharmaceuticals Inc. stock underperforms Tuesday when compared to competitors",
    "url": "https://finnhub.io/api/news?id=a66e3a33dbf479c43f6451123fd66dc3b934c10726caa6d06fd8f286b73ad302",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1733849100,
      "headline": "Regeneron Pharmaceuticals Inc. stock underperforms Tuesday when compared to competitors",
      "id": 131938355,
      "image": "",
      "related": "REGN",
      "source": "MarketWatch",
      "summary": "Regeneron Pharmaceuticals Inc. stock underperforms Tuesday when compared to competitors",
      "url": "https://finnhub.io/api/news?id=a66e3a33dbf479c43f6451123fd66dc3b934c10726caa6d06fd8f286b73ad302"
    }
  },
  {
    "ts": null,
    "headline": "Moderna Stock Is Struggling. BofA Doesn’t See Things Getting Better.",
    "summary": "Moderna Stock Is Struggling. BofA Doesn’t See Things Getting Better.",
    "url": "https://finnhub.io/api/news?id=80246a91644c019e75d3ab88de525c9f65434ec7615517b46410daa9635b1a9f",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1733830920,
      "headline": "Moderna Stock Is Struggling. BofA Doesn’t See Things Getting Better.",
      "id": 134346604,
      "image": "",
      "related": "REGN",
      "source": "MarketWatch",
      "summary": "Moderna Stock Is Struggling. BofA Doesn’t See Things Getting Better.",
      "url": "https://finnhub.io/api/news?id=80246a91644c019e75d3ab88de525c9f65434ec7615517b46410daa9635b1a9f"
    }
  }
]